Search - tctmd.com

Displaying 21 - 40 of 236

Sort: Relevancy | Date

News Conference News HRS 2024

CASA-AF: Similar 3-Year Efficacy for Surgical and Catheter Ablation

L.A. McKeown

May 23, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

L.A. McKeown

April 11, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

News Daily News

M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes

Michael O'Riordan

March 15, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Infective Endocarditis in Opioid Users: Care Must Go Beyond the Heart

Caitlin E. Cox

February 26, 2024

News Daily News

Heart Disease Reigns as Top Killer, but Many Don’t Know It

Yael L. Maxwell

January 26, 2024

News Opinion Off Script

Lessons From 2023’s IVUS/OCT Confusion Can Lead to Better Evidence-Based Practice

Pablo M. Lamelas, MD, MSc

January 03, 2024

News Daily News

Millions of Lives Lost to CVD Each Year: ‘Almanac’ Updates Global Burden

Caitlin E. Cox

December 12, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Daily News

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

Yael L. Maxwell

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Todd Neale

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

Todd Neale

October 24, 2023

Advertisement

CASA-AF: Similar 3-Year Efficacy for Surgical and Catheter Ablation

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Infective Endocarditis in Opioid Users: Care Must Go Beyond the Heart

Heart Disease Reigns as Top Killer, but Many Don’t Know It

Lessons From 2023’s IVUS/OCT Confusion Can Lead to Better Evidence-Based Practice

Millions of Lives Lost to CVD Each Year: ‘Almanac’ Updates Global Burden

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

FDA Approves Paradise Renal Denervation System: What Comes Next?

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content